Business Wire

CA-XSOLLA

30.1.2024 10:01:29 CET | Business Wire | Press release

Share
Xsolla Founder Shurick Agapitov Releases New Book: Once Upon Tomorrow, a Visionary Take on the Metaverse and Its Impact on Global Creativity

Shurick Agapitov, a visionary author and the Founder of Xsolla unveiled his groundbreaking new book, "Once Upon Tomorrow," today. This pioneering work offers a transformative and aspirational vision of the Metaverse, contrasting markedly with mainstream narratives. Agapitov's book is a thought-provoking journey into the possibilities and potential of the Metaverse, providing a unique perspective diverging from the views often presented at industry conferences and by technology CEOs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130496363/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

"In 'Once Upon Tomorrow,' I present a vision of the Metaverse as a vast, inclusive, and transformative space. It's not just a digital frontier but a realm where creativity, innovation, and empowerment converge. This book is my invitation to creators, thinkers, and dreamers across the globe to join in shaping a future where technology amplifies human potential and fosters a world of limitless possibilities. The Metaverse, as I see it, is not about control or confinement but about unleashing the collective creativity and entrepreneurial spirit inherent in all of us," said Shurick Agapitov, Founder of Xsolla and acclaimed author of "Once Upon Tomorrow."

"Once Upon Tomorrow" delves into the untapped potential of the Metaverse, highlighting its capacity to unite emerging and legacy brands, create unforgettable consumer experiences, and enrich cultures globally. Agapitov emphasizes the Metaverse's role in democratizing opportunities and equal access to cutting-edge technologies. His vision extends beyond mere technological innovation, underscoring the Metaverse's potential to empower and reward content creators across the globe. The book also highlights the significant impact of the Metaverse on education, offering hope and opportunities for both children and adults worldwide. Agapitov advocates for a decentralized Metaverse moving away from Silicon Valley's dominance, placing control, profit potential, and freedom in the hands of creative communities.

"Once Upon Tomorrow" is more than just a book about the Metaverse; it's a roadmap to a future where technology serves humanity in all its diversity, fostering financial, social, and creative inclusivity. Agapitov envisions a future where every consumer-facing industry, from fashion to healthcare and entertainment, is transformed. The book also explores the potential impact of the Metaverse on business-to-business sectors, education, city planning, inter-government relations, and non-profit efforts.

Agapitov's insight into the evolution of technology, from the early days of Instagram and Snapchat to the future of immersive applications, is a key highlight of the book. He discusses the roles of various technology stakeholders, including internet hosting providers, website developers, cloud computing experts, infrastructure engineers, and the ongoing need for advanced networking and hardware. "Once Upon Tomorrow" is a visionary piece that invites readers to rethink the Metaverse and its limitless potential.

For additional information and to purchase please visit: onceupontomorrow.com

About Shurick Agapitov

As the founder of Xsolla, Inc., Shurick Agapitov is a highly respected innovator and advisor in gaming, Web3, Metaverse, and fintech. His trailblazing video game company integrates blockchain technology, providing developers with advanced tools and services for more effective game operations and sales. With a global presence, including offices in Los Angeles, Berlin, and Seoul, Xsolla, under Shurick’s leadership, is shaping the future of gaming and the Metaverse, fostering a more decentralized and inclusive industry.

For additional information about Shurick Agapitov please visit: themarque.com or LinkedIn.com

About Xsolla

Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.

For additional information and to learn more, please visit: xsolla.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130496363/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye